IMCR vs. RGEN, PCVX, RVMD, EXEL, HALO, KRYS, CRSP, IBRX, IMVT, and SWTX Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN ) and Immunocore (NASDAQ:IMCR ) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.
Repligen presently has a consensus target price of $197.75, indicating a potential upside of 32.64%. Immunocore has a consensus target price of $81.85, indicating a potential upside of 67.10%. Given Repligen's higher probable upside, analysts plainly believe Immunocore is more favorable than Repligen.
Repligen has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
97.6% of Repligen shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 1.2% of Repligen shares are held by company insiders. Comparatively, 9.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Immunocore had 1 more articles in the media than Repligen. MarketBeat recorded 12 mentions for Immunocore and 11 mentions for Repligen. Immunocore's average media sentiment score of 1.01 beat Repligen's score of 0.23 indicating that Repligen is being referred to more favorably in the media.
Repligen has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Repligen has a net margin of 2.44% compared to Repligen's net margin of -22.60%. Immunocore's return on equity of 3.95% beat Repligen's return on equity.
Repligen received 350 more outperform votes than Immunocore when rated by MarketBeat users. However, 71.83% of users gave Immunocore an outperform vote while only 68.08% of users gave Repligen an outperform vote.
Summary Repligen beats Immunocore on 13 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Immunocore Competitors List
Related Companies and Tools
